Indian government is in dialogue with US biotech giant Moderna, regarding initial successful development of its Covid-19 vaccine candidate, which the drugmaker on Monday announced had achieved 94.5 per cent efficacy in phase 3 trials.
“The government is in dialogue with both domestic and international vaccine manufacturers. Not only with Moderna--the government is also in communication with Pfizer, Serum Institute, Bharat Biotech and Zydus Cadila for their Covid-19 vaccine candidate in terms of safety, immunogenicity and efficacy,” a senior government official said:
The pharma giant Moderna announced on Monday that its coronavirus vaccine was 94.5 per cent effective, based on early results from its large ongoing study.
“The NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against Covid-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5 per cent,” Moderna said in a statement.
This announcement follows that by US giant Pfizer and Germany’s BioNTech last week that their vaccine was found to be more than 90 per cent effective.
{{/usCountry}}This announcement follows that by US giant Pfizer and Germany’s BioNTech last week that their vaccine was found to be more than 90 per cent effective.
{{/usCountry}}